logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. The Oncology Institute "Prof. Dr. Ion Chiricuţă" Cluj-Napoca

Source: Site record.
https://iocn.ro

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

The Oncology Institute Prof Dr Ion Chiricuta (IOCN) is one of Romania’s leading centers for cancer diagnosis, treatment, and research, located in Cluj-Napoca. Named after Ion Chiricuta, the institute plays a vital role in the national oncology network and serves as a major referral center for complex cancer cases. The institute offers comprehensive oncology services, including medical oncology, surgical oncology, radiation therapy, and palliative care. It is equipped with modern technologies that support advanced diagnostics and personalized treatment approaches. IOCN is particularly known for its multidisciplinary care model, ensuring coordinated treatment plans tailored to individual patients. In addition to clinical services, the institute is actively involved in scientific research and participates in international clinical trials, contributing to advancements in cancer therapy. It also plays an important role in medical education and training, supporting the development of…

Source: Trial-derived.
34Total Trials
Source: Trial-derived.
10Recruiting Trials
Source: Trial-derived.
25Active Trials
Source: Trial-derived.
9Completed Trials
Source: Trial-derived.
39Unique Conditions
Source: Trial-derived.
34Unique Sponsors

Conditions

Source: Trial-derived. Carcinoma, Non-Small-Cell Lung (3)Source: Trial-derived. Breast Cancer (2)Source: Trial-derived. Cancer (2)Source: Trial-derived. Melanoma (2)Source: Trial-derived. Non-Small Cell Lung Cancer (2)Source: Trial-derived. Paroxysmal Nocturnal Hemoglobinuria (2)Source: Trial-derived. Advanced Solid Tumors (1)Source: Trial-derived. B-Cell Non-Hodgkin Lymphoma (B-NHL) (1)

Sponsors

Source: Trial-derived. Eli Lilly and Company (4)Source: Trial-derived. Merck Sharp & Dohme LLC (4)Source: Trial-derived. Regeneron Pharmaceuticals (4)Source: Trial-derived. Amgen (3)Source: Trial-derived. Alma Mater Europaea - Slovenia (2)Source: Trial-derived. AstraZeneca (2)Source: Trial-derived. Biobizkaia Health Research Institute (2)Source: Trial-derived. Boehringer Ingelheim (2)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Electronic data capture

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. 12-lead ECG

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Immunogenicity (anti-drug antibody) testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot